Drugs / E004-d3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01737892 | Nov 2012 | asthma | Amphastar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E004-d3 | “PK will be studied using E004-d3 at 125 mcg per inhalation (Arm T).” NCT01737892 ↗ |
| Known as | epinephrine-d3 | “This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled...” NCT01737892 ↗ |
| Route | Inhaled | “Two (2) inhalations of E004-d3 (125 mcg/inhalation), totaling 250 mcg of epinephrine-d3” NCT01737892 ↗ |